Analysts who follow AN2 Therapeutics Inc (ANTX) on average expect it to gain 151.80% over the next twelve months. Those same analysts give the stock an average rating of Buy.
That average rating earns the stock an Analyst Ranking of 18, which means it ranks higher than 18 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating ANTX a Buy today. Find out what this means to you and get the rest of the rankings on ANTX!
Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported.
InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.
What's Happening With AN2 Therapeutics Inc Stock Today?
AN2 Therapeutics Inc (ANTX) stock is down -1.42% while the S&P 500 has gained 0.9% as of 12:20 PM on Wednesday, Mar 6. ANTX has fallen -$0.04 from the previous closing price of $2.82 on volume of 187,612 shares. Over the past year the S&P 500 is up 28.55% while ANTX has fallen -70.55%. ANTX lost -$2.86 per share the over the last 12 months.
Click Here to get the full Stock Report for AN2 Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
